


BMS cell therapy operations and manufacturing

The complexity of delivering autologous CAR T cell therapies is unlike any other traditional biologic or small molecule medicine, using a patient’s own cells to start a highly sophisticated and personalized manufacturing process. Bristol Myers Squibb is advancing the field of cell therapy through novel manufacturing approaches and a well-established supply chain platform across a broad network of state-of-the-art facilities with cutting-edge technologies and highly trained manufacturing teams.

Cell therapy manufacturing footprint and network



By the numbers



15,000+
patients treated in clinical trial and commercial settings



4
clinical and commercial manufacturing sites, and one additional facility underway



~5,000
talented and passionate people, working together with agility and urgency to deliver on the promise of cell therapy to patients



More than
20 years
of experience in cell therapy



2 approved
cell therapies



3+
investigational
cell therapies in clinical trials

Our long-term commitment

As we continue to expand our manufacturing network, BMS is committed to:



Delivering for our patients
Putting people, safety, quality and compliance first



Operational excellence
Advancing OpEx organizational capabilities to deliver organization efficiencies



Driving digital
Advanced digital plan technologies being implemented to ensure reliable supply

Each day, BMS employees around the world work together for patients, who are at the center of everything we do. We continue making significant investments to expand and optimize our global manufacturing network to bring cell therapy treatments to more patients in need.